Tumor-targeted IL-12 combined with tumor resection yields a survival-favorable immune profile.
Zhao Q, Hu J, Mitra A, Cutrera J, Zhang W, Zhang Z, Yan J, Xia X, Mahadeo KM, Livingston JA, Gorlick R, Li S.
Zhao Q, et al. Among authors: hu j.
J Immunother Cancer. 2019 Jun 17;7(1):154. doi: 10.1186/s40425-019-0631-z.
J Immunother Cancer. 2019.
PMID: 31208461
Free PMC article.